May 14, 2024 – Page 12 – Goldea Capital

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

Written by Customer Service on May 14, 2024. Posted in Earnings Releases And Operating Results.

Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in May 2024 Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024 Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027 Company to host conference call and webcast today at 8:00 a.m. ET CHARLOTTESVILLE, Va., May 14, 2024 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results...

Broadwind Announces First Quarter 2024 Results

Written by Customer Service on May 14, 2024. Posted in Earnings Releases And Operating Results.

CICERO, Ill., May 14, 2024 (GLOBE NEWSWIRE) — Broadwind (Nasdaq: BWEN, or the “Company”), a diversified precision manufacturer of specialized components and solutions serving global markets, today announced results for the first quarter 2024. FIRST QUARTER 2024 RESULTS Total revenue of $37.6 million Net income of $1.5 million, or $0.07 per diluted share Total non-GAAP adjusted EBITDA of $4.2 million, or 11.1% of total revenue Ratio of net debt to trailing twelve-month non-GAAP adjusted EBITDA of 0.6x as of March 31, 2024 Broadwind reported first quarter net income of $1.5 million, or $0.07 per diluted share, versus $0.8 million, or $0.04 per diluted share, in the year-ago period. The Company reported adjusted EBITDA, a non-GAAP measure, of $4.2 million in the first quarter compared to $4.1 million in the prior-year period. For...

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

Written by Customer Service on May 14, 2024. Posted in Earnings Releases And Operating Results.

– Generated first quarter 2024 CGuard EPS revenue of $1.51 million, an increase of 22.0% over the first quarter of 2023 – – Announced that an abstract detailing one-year outcomes from the C-GUARDIANS IDE clinical trial of CGuard™ Prime has been accepted for presentation at LINC 2024, to be held May 28-31 – – Named Patrick Geraghty, M.D. and Patrick Muck, M.D. as lead principal investigators for the Company’s CGUARDIANS II clinical trial for Transcarotid Artery Revascularization (TCAR), as well as Dr. William Gray, as advisor to the company – — Management to host investor conference call today, May 14, at 8:30am ET — TEL AVIV, Israel and MIAMI, May 14, 2024 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for...

Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise

Written by Customer Service on May 14, 2024. Posted in Public Companies.

Cash runway extended into July 2025 from previously April 2025 Capital raise strengthens Medigene’s financial position Lead program, MDG1015, on track for IND filing in 3Q 2024 and CTA filing in 4Q 2024 Use of proceeds from recent capital raise further advances plans for first patient enrollment in MDG1015 Phase 1 dose escalation trial by end of 2024, subject to additional financing Planegg/Martinsried, May 14, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, reported that per its ad hoc announcement on May 13, 2024, the Company has extended its cash runway into July 2025 and thus amended its 2024 financial guidance. “We are very pleased to announce that the recently completed capital raise...

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

Written by Customer Service on May 14, 2024. Posted in Public Companies.

Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Plan to report clinical data for XTX101 and XTX301, a tumor-activated IL-12, in the fourth quarter of 2024 Advancing research-stage pipeline of tumor-activated bispecifics and immune cell engagers Anticipate cash runway into the second quarter of 2025 WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the first quarter ended March 31, 2024. “In the first...

HealthEquity Closes Acquisition of BenefitWallet HSA Portfolio

Written by Customer Service on May 14, 2024. Posted in Mergers And Acquisitions.

Welcomes clients and members to its best-in-class platform DRAPER, Utah, May 14, 2024 (GLOBE NEWSWIRE) — HealthEquity, Inc. (Nasdaq: HQY) (“HealthEquity”), the leader in Health Savings Account (HSA) and consumer-directed benefits administration, is pleased to announce the completed transfer of Conduent’s (Nasdaq: CNDT) BenefitWallet HSA portfolio. HealthEquity Chief Executive Officer, Jon Kessler said, “We are thrilled to welcome BenefitWallet clients and members as partners on our mission to save and improve lives by empowering healthcare consumers. We are committed to leading the health savings space by delivering remarkable service, deepening partnerships, and driving outcomes that matter to them.” HealthEquity welcomed more than 616,000 HSA members with approximately $2.7 billion in HSA Assets, of which...

Navios Maritime Partners L.P. Reports Financial Results for the First Quarter Ended March 31, 2024

Written by Customer Service on May 14, 2024. Posted in Earnings Releases And Operating Results.

Revenue: $318.6 million for Q1 2024 Net Income: $73.4 million for Q1 2024 Earnings per common unit: $2.38 for Q1 2024 Net cash from operating activities: $94.4 million for Q1 2024 EBITDA: $166.2 million for Q1 2024 Sales and purchases: $ 92.6 million gross sale proceeds YTD 2024 $ 9.8 million completed in Q1 2024 $82.8 million to be completed in Q2 2024 $245.7 million acquisitions YTD 2024 $129.1 million acquisition of two newbuilding scrubber-fitted aframax/LR2 tankers $116.6 million acquisition of four Japanese-built kamsarmaxes Three newbuilding vessels delivered YTD 2024 $3.3 billion remaining contracted revenue $0.05 per unit cash distribution for Q1 2024 MONACO, May 14, 2024 (GLOBE NEWSWIRE) — Navios Maritime Partners L.P. (“Navios Partners”) (NYSE: NMM), an international owner and operator of dry...

SoFi Announces Monthly Distributions on $THTA (13.80%)

Written by Customer Service on May 14, 2024. Posted in Dividend Reports And Estimates.

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) — SoFi, a leading provider of thematic and income ETFs, today announced monthly distributions on the SoFi Enhanced Yield ETF (THTA). Distribution as of 05/14/2024 ETFTicker Distributionper Share DistributionRate * 30-Day SEC Yield** Ex-Date RecordDate PaymentDate THTA $0.2326 13.80% 4.26% 05/15/2024 05/16/2024 05/17/2024 Inception date: 11/15/2023Click here to view standardized performance for THTA. THTA, launched in partnership with Tidal Investments LLC and ZEGA Financial LLC, seeks current income by combining a strategy of holding U.S. government securities, including U.S. Treasury Bills and U.S. Treasury Bonds, with a “credit spread” option strategy to seek to generate enhanced yield. About SoFiOur mission is to help people reach financial independence to realize their ambitions....

Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update

Written by Customer Service on May 14, 2024. Posted in Earnings Releases And Operating Results.

Management to host a conference call today at 8:30 am ET WM pivotal study data to be announced in June FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended March 31, 2024, and provided a corporate update. “We plan to announce data from our CLOVER WaM pivotal study evaluating iopofosine I 131 in Waldenstrom’s macroglobulinemia in June and are on track to submit our NDA in the second half of 2024. We remain pleased with patient enrollment in the phase 1b pediatric high-grade glioma study and expect to announce data in the second half of 2024,” said James Caruso, president, and CEO of Cellectar....

Hudbay Delivers Strong First Quarter 2024 Results

Written by Customer Service on May 14, 2024. Posted in Earnings Releases And Operating Results.

TORONTO, May 14, 2024 (GLOBE NEWSWIRE) — Hudbay Minerals Inc. (“Hudbay” or the “company”) (TSX, NYSE: HBM) today released its first quarter 2024 financial results. All amounts are in U.S. dollars, unless otherwise noted. All production and cost amounts reflect the Copper Mountain mine on a 100% basis, with Hudbay owning a 75% interest in the mine. “We delivered another consecutive quarter of strong operational and financial performance with steady free cash flow generation and further debt reduction,” said Peter Kukielski, President and Chief Executive Officer. “These results demonstrate the strength of our diversified operating base, with continued contributions from the high-grade Pampacancha deposit in Peru, better-than-planned gold production in Manitoba and benefits starting to be realized from operational stabilization...

Day: May 14, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice